LLY Stock Summary and Trading Ideas (Eli Lilly And Company | NYSE:LLY)

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly And Company trades on the NYSE stock market under the symbol LLY.

As of December 8, 2025, LLY stock price declined to $997.59 with 2,760,930 million shares trading.

LLY has a beta of 0.47, meaning it tends to be less sensitive to market movements. LLY has a correlation of 0.03 to the broad based SPY ETF.

LLY has a market cap of $892.86 billion. This is considered a Mega Cap stock.

Last quarter Eli Lilly And Company reported $18 billion in Revenue and $7.02 earnings per share. This beat revenue expectation by $2 billion and exceeded earnings estimates by $1.06.

In the last 3 years, LLY traded as high as $1,111.99 and as low as $302.14.

The top ETF exchange traded funds that LLY belongs to (by Net Assets): VTI, VOO, IVV, SPY, VUG.

LLY has outperformed the market in the last year with a return of +21.4%, while the SPY ETF gained +13.7%. In the last 3 month period, LLY beat the market returning +35.3%, while SPY returned +5.6%. However, in the most recent 2 weeks LLY has underperformed the stock market by returning -6.8%, while SPY returned +2.2%.

LLY support price is $991.96 and resistance is $1,028.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LLY shares will trade within this expected range on the day.